OBJECTIVES
OBJECTIVES
The General Objective is to develop a human clinical protocol for using dopaminergic allosteric modulators to treat dysfunctional eating behaviors, through a translational framework integrating preclinical, human profiling and clinical trial phases.
Use animal models to simulate binge-type and restrictive-type eating patterns, characterizing how positive and negative dopaminergic allosteric modulators affect the brain's reward system through neuroimaging and magnetic resonance spectroscopy.
Conduct a comprehensive human profiling study using a multimodal assessment strategy (heart rate variability, galvanic skin response, facial electromyography and validated psychometric questionnaires) to identify neurobehavioral patterns and distinct dopaminergic reward profiles across obesity, anorexia and bulimia.
Develop a double-blind, placebo-controlled clinical trial protocol to evaluate the efficacy of selected dopaminergic allosteric modulators, with participants stratified according to the psychophysiological and behavioral profiles established in Phase II.